Characteristics of the 52 consecutive patients treated with induction chemotherapy according to OPN status
| . | Total patients, n = 52 . | OPN high, n = 25 (48%) . | OPN low, n = 27 (52%) . | P . |
|---|---|---|---|---|
| Median OPN level (range) | 0.20 (0.00-13.1) | 0.775 (0.23-13.7) | 0.00 (0.00-0.20) | N/A |
| Mean age, y, mean ± SD | 51 ± 17 | 55 ± 15 | 48 ± 18 | .2 |
| Male, n (%) | 29 (55) | 15 (60) | 14 (51) | .7 |
| Median WBC count, ×109/L (range) | 11.9 (1.3-300) | 15.9 (1.3-300) | 7 (1.68-171) | .7 |
| Median BM blasts, % (range) | 67 (20-99) | 55 (22-92) | 70 (20-99) | .8 |
| FAB, n (%) | ||||
| M0 | 2 (4) | 1 (4) | 1 (4) | N/A |
| M1 | 19 (36) | 10 (40) | 9 (33) | N/A |
| M2 | 14 (26) | 8 (32) | 6 (22) | N/A |
| M4 | 7 (13) | 2 (8) | 5 (18) | N/A |
| M5 | 7 (13) | 3 (12) | 4 (15) | N/A |
| M6 | 2 (7) | 1 (4) | 2 (7) | .9 |
| Cytogenetic subgroup, n (%) | ||||
| Unfavorable | 11 (21) | 7 (28) | 4 (14) | N/A |
| Intermediate | 37 (71) | 15 (60) | 22 (81) | N/A |
| Favorable | 3 (6) | 3 (12) | 0 (0) | .07 |
| FLT3 mutation, n (%) | 14/20 (70) | 5/8 (63) | 9/12 (75) | .6 |
| Induction chemotherapy, n (%) | 52 (100) | 25 (100) | 27 (100) | < .99 |
| Allotransplantation, n (%) | 11/52 (21) | 4/25 (16) | 7/27 (25) | .5 |
| . | Total patients, n = 52 . | OPN high, n = 25 (48%) . | OPN low, n = 27 (52%) . | P . |
|---|---|---|---|---|
| Median OPN level (range) | 0.20 (0.00-13.1) | 0.775 (0.23-13.7) | 0.00 (0.00-0.20) | N/A |
| Mean age, y, mean ± SD | 51 ± 17 | 55 ± 15 | 48 ± 18 | .2 |
| Male, n (%) | 29 (55) | 15 (60) | 14 (51) | .7 |
| Median WBC count, ×109/L (range) | 11.9 (1.3-300) | 15.9 (1.3-300) | 7 (1.68-171) | .7 |
| Median BM blasts, % (range) | 67 (20-99) | 55 (22-92) | 70 (20-99) | .8 |
| FAB, n (%) | ||||
| M0 | 2 (4) | 1 (4) | 1 (4) | N/A |
| M1 | 19 (36) | 10 (40) | 9 (33) | N/A |
| M2 | 14 (26) | 8 (32) | 6 (22) | N/A |
| M4 | 7 (13) | 2 (8) | 5 (18) | N/A |
| M5 | 7 (13) | 3 (12) | 4 (15) | N/A |
| M6 | 2 (7) | 1 (4) | 2 (7) | .9 |
| Cytogenetic subgroup, n (%) | ||||
| Unfavorable | 11 (21) | 7 (28) | 4 (14) | N/A |
| Intermediate | 37 (71) | 15 (60) | 22 (81) | N/A |
| Favorable | 3 (6) | 3 (12) | 0 (0) | .07 |
| FLT3 mutation, n (%) | 14/20 (70) | 5/8 (63) | 9/12 (75) | .6 |
| Induction chemotherapy, n (%) | 52 (100) | 25 (100) | 27 (100) | < .99 |
| Allotransplantation, n (%) | 11/52 (21) | 4/25 (16) | 7/27 (25) | .5 |
All patients were treated with standard AML induction therapy that included cytarabine, idarubicin, and etoposide followed by consolidation chemotherapy. Patients with APML(M3) treated with all-trans retinoic acid–based regimens were excluded. The mean age of our cohort was 51 years with a median follow-up of living patients at 5 years. The 5-year OS rate was 23%. FLT3 mutation status (internal tandem duplication of FLT3 receptor or D835 point mutation) was available for 20 patients (38%). Differences in the distribution of patients between FAB subgroups and cytogenetic risk groups were tested for categorical variables by χ2 test. Differences in continuous variables were tested with the Student t test or Mann-Whitney U test when appropriate.
WBC indicates white blood cell; N/A, not applicable; and cytogenetic subgroups, karyotype risk groups were defined according to the MRC10 criteria.